Q2 2026 13F · SEC CIK 2111609

Ishara Investments LP

Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $136.1M
Reported positions: 41
Holdings vs S&P 500, 3 yrs: —
Assets under management: $259.1M

Ishara Investments LP is a hedge fund that reported 41 positions worth $136.1M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Acadia Pharmaceuticals Inc (ACAD, 7.6%), Xeris Biopharma Holdings Inc (XERS, 7.2%), Biomarin Pharmaceutical Inc (BMRN, 6.0%).

Ishara Investments LP holdings all 41 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Ishara Investments LP 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
ACADAcadia Pharmaceuticals Inc	7.6%	2.8%	410,000	+233.3%	$10.4M
XERSXeris Biopharma Holdings Inc	7.2%	6.0%	1,230,000	+20.0%	$9.7M
BMRNBiomarin Pharmaceutical Inc	6.0%	4.7%	143,500	+75.0%	$8.2M
PRAXPraxis Precision Medicines I	5.5%	7.3%	22,550	+0.0%	$7.5M
RAREUltragenyx Pharmaceutical in	5.0%	3.7%	205,000	+17.6%	$6.8M
AGIOAgios Pharmaceuticals Inc	4.5%	New	164,000	—	$6.1M
INSMInsmed Inc	4.0%	New	51,250	—	$5.5M
CRNXCrinetics Pharmaceuticals in	3.9%	New	143,500	—	$5.4M
ZNTLZentalis Pharmaceuticals Inc	3.7%	2.9%	1,025,000	-16.7%	$5.0M
PCVXVaxcyte Inc	3.5%	3.4%	82,000	+42.9%	$4.8M
ANNXAnnexon Inc	3.4%	1.0%	820,000	+370.6%	$4.7M
TVTXTravere Therapeutics Inc	3.4%	3.3%	82,000	-25.9%	$4.7M
TNXPTonix Pharmaceuticals Hldg C	3.2%	New	338,250	—	$4.3M
BBIOBridgebio Pharma Inc	3.1%	New	57,400	—	$4.3M
AXSMAxsome Therapeutics Inc.	2.9%	7.0%	16,400	-60.0%	$4.0M
CTNMContineum Therapeutics Inc	2.5%	1.9%	205,000	+44.4%	$3.4M
LXRXLexicon Pharmaceuticals Inc	2.2%	1.4%	1,271,000	+40.9%	$3.1M
KURAKura Oncology Inc	2.2%	New	276,750	—	$3.0M
DBVTDbv Technologies S A	2.2%	2.2%	184,500	+80.0%	$3.0M
GMABGenmab A/s	2.1%	2.2%	102,500	+25.0%	$2.8M
CYTKCytokinetics Inc	2.1%	New	32,800	—	$2.8M
MLYSMineralys Therapeutics Inc	2.0%	2.2%	102,500	+25.0%	$2.8M
SLNSilence Therapeutics PLC	1.8%	0.7%	55,350	-60.6%	$2.4M
NUVBNuvation Bio Inc	1.5%	New	369,000	—	$2.1M
WVEWave Life Sciences Ltd	1.4%	New	328,000	—	$1.9M
NKTRNektar Therapeutics	1.4%	New	26,650	—	$1.9M
SRRKScholar Rock Hldg Corp	1.2%	2.9%	30,750	-46.4%	$1.7M
ELVNEnliven Therapeutics Inc	1.2%	New	32,800	—	$1.7M
ALNYAlnylam Pharmaceuticals Inc	1.1%	1.7%	5,125	+0.0%	$1.5M
BEAMBeam Therapeutics Inc	1.0%	1.4%	41,000	-28.6%	$1.4M
829401108Sionna Therapeutics Inc	1.0%	2.0%	123,000	+150.0%	$1.4M
ORICOric Pharmaceuticals Inc	1.0%	1.3%	123,000	+20.0%	$1.3M
NAMSNewamsterdam Pharma Company	0.9%	1.2%	36,900	+0.0%	$1.3M
VRTXVertex Pharmaceuticals Inc	0.9%	New	2,460	—	$1.2M
SPRYArs Pharmaceuticals Inc	0.8%	New	143,490	—	$1.1M
MNPRMonopar Therapeutics Inc	0.8%	New	12,300	—	$1.1M
ERASErasca Inc	0.6%	New	41,000	—	$751K
VERAVera Therapeutics Inc	0.3%	3.3%	10,250	-87.5%	$440K
IMTXImmatics NV	0.2%	1.5%	30,750	-80.0%	$311K
MREOMereo Biopharma Group PLC	0.2%	New	768,750	—	$244K
GOSSGossamer Bio Inc	0.1%	0.3%	820,000	+0.0%	$135K

What Ishara Investments LP bought and sold in Q2 2026, against Q1 2026.

Share counts compared with the Q1 2026 13F; a split also changes share counts.

How the holdings did against the S&P 500.

1 year: —
3 years: —
5 years: —

A portfolio of the filer's 20 largest 13F positions, weighted by value and rebuilt each quarter on the day the filing became public. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$136.1M	41
Q1 2026	$99.0M	36
Q4 2025	$85.9M	37

Questions about Ishara Investments LP's portfolio

What stocks does Ishara Investments LP own?

Ishara Investments LP's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 41 positions worth $136.1M. The largest are Acadia Pharmaceuticals Inc (ACAD) at 7.6%, Xeris Biopharma Holdings Inc (XERS) at 7.2%, Biomarin Pharmaceutical Inc (BMRN) at 6.0%, Praxis Precision Medicines I (PRAX) at 5.5% and Ultragenyx Pharmaceutical in (RARE) at 5.0%.

What did Ishara Investments LP buy last quarter?

In Q2 2026, Ishara Investments LP added a new position in Agios Pharmaceuticals Inc (AGIO), a new position in Insmed Inc (INSM), a new position in Crinetics Pharmaceuticals in (CRNX), a new position in Tonix Pharmaceuticals Hldg C (TNXP), a new position in Bridgebio Pharma Inc (BBIO), Annexon Inc (ANNX) (+370.6% shares), Acadia Pharmaceuticals Inc (ACAD) (+233.3% shares) and Sionna Therapeutics Inc (+150.0% shares), compared with its Q1 2026 filing.

What did Ishara Investments LP sell last quarter?

In Q2 2026, Ishara Investments LP sold all of Kalvista Pharmaceuticals Inc (KALV), sold all of Amicus Therapeutic (FOLD), sold all of Verastem Inc (VSTM), sold all of Arrowhead Pharmaceuticals in (ARWR), sold all of Moonlake Immunotherapeutics (MLTX), Vera Therapeutics Inc (VERA) (-87.5% shares), Immatics NV (IMTX) (-80.0% shares) and Silence Therapeutics PLC (SLN) (-60.6% shares), compared with its Q1 2026 filing.

When is Ishara Investments LP's next 13F filing due?

13F filings are due 45 days after each quarter ends. Ishara Investments LP's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Ishara Investments LP manage?

Ishara Investments LP reported $259.1M of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $136.1M.